Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.16849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Hao Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province for Distinguished Young Scholar, National Natural Science Foundation of China, National Key R&D Program of China.
Abstract (Originalsprache)
Background and Aims In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes.
Methods
We conducted a retrospective cohort study to compare the risk of transitioning to immune active phase between inactive and indeterminate CHB and the incidence of hepatocellular carcinoma (HCC) and cirrhosis between untreated patients with indeterminate CHB (at baseline and throughout follow‐up) and those who received treatment, following standard AASLD 2018 guidance.
Results
The risk of transitioning to the immune active phase over 3, 5, and 10 years was 6.3%, 8.9%, and 14.2%, respectively, for inactive phase patients ( n = 104). For HBeAg‐negative indeterminate phase patients ( n = 194), the risk was significantly higher at 23.0%, 31.9%, and 38.2%, and for HBeAg‐positive indeterminate phase patients ( n = 140), it was 40.4%, 52.0%, and 55.0% ( p < 0.001). Inverse probability of treatment weighting (IPTW) was utilized to balance the groups of treated and untreated indeterminate patients. Following IPTW adjustment, the Kaplan–Meier curve analysis indicates that the risk of HCC and cirrhosis among untreated patients ( n = 294) is higher than that among treated patients ( n = 76), ( p = 0.015 and 0.007, respectively). In the multivariable analysis, antiviral therapy remained an independent predictor of a reduced risk of HCC (aHR 0.128, 95% CI 0.031–0.522, p = 0.005) and cirrhosis (aHR 0.148, 95% CI 0.044–0.496, p = 0.002).
Conclusion
The indeterminate phase patients had a high‐risk transition to active phase, and antiviral therapy can reduce the incidence of developing HCC and cirrhosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China.
- Guangdong Provincial Key Laboratory of Liver Disease Research, Guangzhou, People's Republic of China.
- Gastrointestinal Endoscopy Center, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, People's Republic of China.
ORCID-Profile: Bin Wu, Yidong Yang
Förderung
- Natural Science Foundation of Guangdong Province for Distinguished Young Scholar
- National Natural Science Foundation of China
- National Key R&D Program of China
Zitieren
APA
Jiang, H., Yu, H., Huang, Y., Li, M., Yang, B., Xi, X., Lei, Y., Wu, B., & Yang, Y. (2025). Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16849
Vancouver
Jiang H, Yu H, Huang Y, Li M, Yang B, Xi X, et al. Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16849
BibTeX
@article{Jiang2025,
author = {Jiang, Hao and Yu, Hongsheng and Huang, Yinan and Li, Mingkai and Yang, Bilan and Xi, Xiaoli and Lei, Yiming and Wu, Bin and Yang, Yidong},
title = {Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.16849}
}
EUVIMED